Targeting AMPK for cancer prevention and treatment

Weidong Li; Shakir M. Saud; Matthew R. Young; Guohong Chen; Baojin Hua

doi:10.18632/oncotarget.3629

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeting AMPK for cancer prevention and treatment

Weidong Li, Shakir M. Saud, Matthew R. Young, Guohong Chen and Baojin Hua _

PDF | HTML | How to cite

Oncotarget. 2015; 6:7365-7378. https://doi.org/10.18632/oncotarget.3629

Metrics: PDF 5818 views | HTML 7092 views | ?

Abstract

Weidong Li1,3,*, Shakir M. Saud2,3,*, Matthew R. Young3, Guohong Chen4, Baojin Hua1

1 Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

2 Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA

3 Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA

4 Department of Urinary Surgery, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

* These authors have contributed equally to this work

Correspondence to:

Baojin Hua, email:

Guohong Chen, email:

Keywords: AMP activated kinase, cancer, prevention, treatment

Received: February 02, 2015 Accepted: February 26, 2015 Published: March 20, 2015

Abstract

AMP-activated protein kinase (AMPK) is an important mediator in maintaining cellular energy homeostasis. AMPK is activated in response to a shortage of energy. Once activated, AMPK can promote ATP production and regulate metabolic energy. AMPK is a known target for treating metabolic syndrome and type-2 diabetes; however, recently AMPK is emerging as a possible metabolic tumor suppressor and target for cancer prevention and treatment. Recent epidemiological studies indicate that treatment with metformin, an AMPK activator reduces the incidence of cancer. In this article we review the role of AMPK in regulating inflammation, metabolism, and other regulatory processes with an emphasis on cancer, as well as, discuss the potential for targeting AMPK to treat various types of cancer. Activation of AMPK has been found to oppose tumor progression in several cancer types and offers a promising cancer therapy. This review evaluates the evidence linking AMPK with tumor suppressor function and analyzes the molecular mechanisms involved. AMPK activity opposes tumor development and progression in part by regulating inflammation and metabolism.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3629

Publication Alerts

Reviews:

Targeting AMPK for cancer prevention and treatment

Abstract